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1. Introduction
  Parkinson’s disease (PD) is a degenerative disease of 
the central nervous system, which has become one of the 
most important diseases that severely influence humans 
especially aged people. Pathological characteristics of PD 
include absence of substantia nigra dopaminergic neuron 
and formation of Lewy body, which could occur several 
years before the appearance of typical motor symptoms[1]. 
Conventional treatment with levodopa could remit clinical 
symptoms but could not prevent the disease progression; in 
addition, long-term drug therapy could also induce severe 
adverse effects[2]. Statins is widely used in clinical practices 
in treating hyperlipemia. Clinical studies demonstrated 
that statins could remit motor and non-motor symptoms of 
patients with PD, and delay the progression of disease[3]. In 
the present study, the protective effect of simvastatin (simv) 
on neurons of rats with lipopolysaccharide (LPS)-induced 
PD was investigated.
2. Materials and methods
2.1. Animals
  Forty-five male adult Sprague-Dawley (SD) rats, weighing 
230-250 g (Laboratory Animal Centre of Tongji Medical 
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College, Huazhong Science and Technology University, 
China), were divided into 3 groups, namely control group, 
LPS group, and LPS+simv group (15 rats in each group).
2.2. Regents and equipment
  LPS and apomorphine were purchased from Sigma-Aldrich 
(America), enzyme-linked immunosorbent assay (ELISA) Kit 
for tumor necrosis factor-alpha (TNF-毩) was purchased 
from Elabscience Biotechnology Co., Ltd. (Wuhan, China), 
monoclonal antibody of tyrosine hydroxylase (TH) was 
purchased from Abcam (America), and glial fibrillary 
acidic protein (GFAP) polyclonal rabbit anti rat antibody 
was purchased from Bioss Biotechnology Co., Ltd. (Beijing, 
China). Rat stereotactic instrument was purchased from 
Ruiward Company (Shenzhen, China).
2.3. Model induction and treatment
  Two µL of LPS (5 毺g/毺L) was stereotaxically injected into 
the right substantia nigra pars compacta (SNpc) to induce 
hemiparkinsonian rat model. Intraperitoneal injection 
of simvastatin (5 mg/kg) was performed for the rats in 
the LPS+simv group at 5 pm each day (1 hour before the 
operation), while intraperitoneal injection of same volume 
of normal saline was performed for the rats in the control 
and LPS groups. Intraperitoneal injection of 10% chloral 
hydrate (3.5 mL/kg) was given for anesthesia, and then the 
rats were horizontally fixed in the stereotactic instrument 
with the ear bar parallel to the line connecting bilateral 
ears, and the height of incisor bar of -3.3 mm. Bregma was 
considered as origin of coordinates, and the coordinate of 
substantia nigra was A-5.0 mm, R-2.0 mm, and DV-7.6 mm. 
For the rats in the LPS and LPS+simv groups, 2 毺L of LPS 
was stereotaxically injected into the right SNpc, while 2 毺L 
of normal saline was injected into the right SNpc for the rats 
in the control group; the injection speed was 0.4 毺L/min, 
and the needle was retained for 10 min and then retreated 
slowly.
2.4. Behavioral test
  Apomorphine (0.05 mg/kg) was subcutaneously injected. 
Two weeks later, the time taken to rotate the head to the side 
contralateral to destruction was recorded and the rotation 
cycles were recorded every 5 min for 30 min.
2.5. Immunohistochemical examination
  Striatum and substantia nigra were collected according 
to Paxinos and Franklin atlas. Paraffin sections of the 
tissues were performed of 5 毺m thickness. One section was 
selected from each 6 continuous sections, and 2 sections 
were selected for each rat. The TH (1:200 dilution) and GFAP 
(1:100 dilution) staining were performed. Six visual fields of 
striatum or substantia nigra were selected on the left and 
right sides of each section (with 3 visual fields on each side), 
observed, and photographed at same amplification factor (伊
20/100/200/400) and at same light intensity. Image-Pro Plus 
6.0 software was used to analyze the mean optical density 
(OD) of TH positive regions of striatum, TH positive cell 
count at substantia nigra, and mean OD of GFAP positive 
regions of substantia nigra.
2.6. TNF-毩 expression at substantia nigra 
  TNF-毩 expression at substantia nigra was determined 
using ELISA. In brief, the rats were decapitated and the 
brains were collected, and then the substantia nigra was 
collected on ice, homogenated, and centrifuged at 4 曟, 
12 000 rpm for 10 minutes. Supernatant was collected, and 
then the TNF-毩 level was determined according to the 
instructions of radioimmunoassay kit.
2.7. Statistical analysis
  The SPSS software, Version 17.0, was used for the statistical 
analyses. Data were described as means and standard 
divisions, and compared using t-test or analyses of 
variances. A P<0.05 was considered statistically significant.
3. Results
3.1. Effects of simvastatin on rotational behavior of the rats
  Two weeks after the intraperitoneal apomorphine 
administration, no rotational behavior was found for the 
rats in the control group, while increased rotation cycles 
were found for the rats in the LPS group [mean: (146.8依
7.2) cycles/30 min, P<0.01]. However, in LPS+simv group 
(rats received 14 continuous days of treatment with 5 mg/kg 
simvastatin), the rotational behavior of the rats significantly 
decreased as compared with the rats in the LPS group [(79.5依
9.4) cycles/30 min, P<0.05].
3.2. Immunohistochemical staining result of TH
  The TH positive cell count in the injection region of 
substantia nigra or striatum, as well as OD in striatum in the 
control group was not significantly different from LPS group 
or LPS+simv group (P>0.05). In contrast, TH positive neurons 
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were significantly decreased in the substantia nigra of the 
rats in LPS group,  protuberances and fiber connection of the 
cells were also found reduced, attenuated, and shortened 
significantly; TH positive reaction in striatum and staining 
was also significantly reduced (Figure 1B). The TH positive 
cell count in substantia nigra was found significantly 
increased in LPS+simv groups (P<0.05); TH positive response 
(OD value) and staining in striatum was also increased 
significantly (Figure 1C). Figure 2 shows the percentage of 
dopaminergic neuron loss in the 3 groups. The 78.6% of the 
dopaminergic neurons in the damaged side was found lost 
as compared with the undamaged side in LPS group (P<0.01), 
while TH positive neurons in LPS+simv group recovered to 
the level of 59.8% of the undamaged side (P<0.05).
 
Figure 1. A, B, and C shows TH positive cells in the striatum of 
control, LPS, and LPS+simv groups (暳400 ).
1.2
1.0
0.8
0.6
0.4
0.2
0
Su
rv
iv
al
ra
ti
o 
of
 D
A
 n
eu
ro
n
(i
nj
ec
te
ed
 to
 n
on
-
in
je
ct
ed
 s
id
e)
***
**
 Control                         LPS                        LPS+simv
 
Figure 2. Ratio of dopaminergic neuron in the damaged side to non-
damaged side in the 3 groups.
3.3. Changes in GFAP positive cells of substantia nigra
  The GFAP positive cell count was found decreased in the 
undamaged substantia nigra of the rats in control, LPS, and 
LPS+simv groups, the star-shaped cell body was found with 
shallow staining (Figure 3A), and the difference among these 
3 groups was not statistically significant (P>0.05). The count 
of GFAP positive cells increased significantly, protuberances 
shortened, and staining increased after 2-weeks of 
administration of LPS into substantia nigra (Figure 3B), 
with significant difference in mean OD as compared with 
control group (P<0.05); whereas, the count of activated GFAP 
positive cells were significantly decreased in the LPS+simv 
group as compared with LPS group (Figure 3C), and the OD 
difference was statistically significant (P<0.05) (Figure 4).
 
Figure 3. GFAP expression (*400伊) A: control group; B: LPS group; 
C: LPS+simv group.
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Figure 4. Mean OD value of GFAP in the 3 groups. 
***P<0.01, compared with the control group;  ###P<0.05, compared 
with the LPS group.
3.4. TNF-毩 change in substantia nigra
  TNF-毩 expression was significantly increased in LPS 
group (LPS injected in substantia nigra) as compared with 
control group (P<0.01), while treatment with simvastatin 
effectively reduced the TNF-毩 expression (P<0.05) (Figure 
5).
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Figure 5. TNF-毩 expression in damaged substantia nigra of the rats.
##P<0.05, compared with the control group; #P<0.05, compared with 
LPS group.
4. Discussion
  Etiology and pathogenesis of PD is not clearly understood to 
date. However, previous studies suggested that PD is caused 
by multi-factors including genetic factors, environmental 
factors,  oxidative stress, and energy metabolism 
abnormalities[4]. Although no effective treatment is available 
for PD to date, neuroprotective treatments have been widely 
used to manage PD.
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  Santiago et al[5] found that the level of dopamine was 
significantly increased after treatment with simvastatin 
in inflammatory rat model (induced by LPS injection 
into striatum)[5], suggesting that simvastatin could result 
in neuroprotective effects. Mutez et al[6] retrospectively 
analyzed data from 419 PD patients with or without lipid-
lowering therapy (statins or fibrates), and found that the 
time of PD onset delayed 9 and 8.7 years, respectively, in 
the patients with lipid-lowering therapy than those without 
lipid-lowering therapy. The findings of the present study 
showed that simvastatin treatment could significantly reduce 
rotational behavior induced by apomorphine as compared 
with the rats in the control group (P<0.05), suggesting that 
simvastatin could effectively improve rotational behavior 
induced by apomorphine. In addition, TH positive cells in 
substantia nigra and striatum were increased significantly 
(both P<0.05), TH positive response (OD) and staining in 
striatum increased, and TH positive neurons recovered 
to 59.8% level of the undamaged side (P<0.05), suggesting 
that simvastatin could effectively protect cell body of 
dopaminergic neurons in both substantia nigra and striatum, 
and the improvement of motor symptoms could be the results 
of protective effects on dopaminergic neurons in substantia 
nigra.
  Recent studies showed that inflammation play an important 
role in PD[7]. As dopaminergic neurons are susceptible to 
inflammations and oxidative damages, neuroinflammation 
mediated by glial cells has attracted more and more 
attention. Previous studies revealed abnormalities in 
astrocytes and microglia’s in patients with PD[8], suggesting 
the involvement of these two cells in the development of 
early stage PD. The exact effects of abnormal changes of 
astrocytes in patients with PD are not clearly understood. 
Recent studies showed that astrocytes could release soluble 
molecules including glutathione and neurotrophin, which 
could ensure the survival and normal function of neurons; 
in addition, astrocytes could also release cytokines and 
chemokines to prevent neurons from damages[9]. Increased 
expression of several inflammatory factors including 
interleukin (IL)-1, IL-6, and TNF-毩 could be found in such 
pathological processes[10]. TNF-毩 is a pro-inflammatory 
factor which could stimulate astrocytes to release more 
cytokines and chemokines, accelerate and expand 
inflammations, and thus induce neurocyte injuries[11]. The 
GFAP could only be found in astrocytes, and thus could be 
used as a specific biomarker in identifying astrocytes. The 
present study showed that rats with LPS induced lateral 
substantia nigra and striatum destructions had increased 
number of astrocytes and OD (P<0.05), suggesting the 
increased immunoreactivity; GFAP positive cells and OD 
were significantly decreased in simvastatin treatment group 
as compared with LPS group (P<0.05). Moreover, TNF-
毩 secretion and expression decreased significantly in 
simvastatin treatment group as compared with LPS group 
(P<0.05). These results suggested that simvastatin could 
reduce the number and inhibit the activation of GFAP 
positive astrocytes in LPS induced rat models and decrease 
the TNF-毩 release. Hence, the author hypothesize that 
simvastatin could reduce the expression of TNF-毩, inhibit 
astrocyte activation, and thus reduce the release of cytotoxic 
substances from activated astrocytes, which results in 
protective effects on dopaminergic neurons in substantia 
nigra. However, further studies are needed to investigate the 
mechanism of protective effects of simvastatin on PD.
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